Skip to main content Accessibility help
×
Home

Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact

  • C. M. Prado (a1), S. J. Cushen (a2), C. E. Orsso (a1) and A. M. Ryan (a2)

Abstract

Our understanding of body composition (BC) variability in contemporary populations has significantly increased with the use of imaging techniques. Abnormal BC such as sarcopenia (low muscle mass) and obesity (excess adipose tissue) are predictors of poorer prognosis in a variety of conditions or clinical situations. As a catabolic illness, a defining feature of cancer is muscle loss. Although the conceptual model of wasting in cancer is typically conceived as involuntary weight loss leading to low body weight, recent studies have shown that both sarcopenia and cachexia can be present with obesity. The combination of low muscle and high adipose tissue (sarcopenic obesity) is an emerging abnormal BC phenotype prevalent across the body weight, and hence BMI spectra. Sarcopenia and sarcopenic obesity in cancer are in most instances occult conditions, which have been independently associated with higher incidence of chemotherapy toxicity, shorter time to tumour progression, poorer outcomes of surgery, physical impairment and shorter survival. Although the mechanisms are yet to be fully understood, the associations with poorer clinical outcomes emphasise the value of nutritional assessment as well as the need to develop appropriate interventions to countermeasure abnormal BC. Sarcopenia and sarcopenic obesity create diverse nutritional requirements, highlighting the compelling need for a more comprehensive and differentiated understanding of energy and protein requirements in this heterogeneous population.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: C. M. Prado, email carla.prado@ualberta.ca

References

Hide All
1. Schols, AM (2015) Nutritional advances in patients with respiratory diseases. Eur Respir Rev 24, 1722.
2. Sheean, PM, Peterson, SJ, Gomez Perez, S et al. (2014) The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. JPEN J Parent Enteral Nutr 38, 873879.
3. Staal-van den Brekel, AJ, Schols, AM & Dentener, MA (1997) Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax 52, 338341.
4. Montano-Loza, AJ, Meza-Junco, J, Prado, CM et al. (2012) Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 10, 166173, 73e1.
5. Montano-Loza, AJ, Angulo, P, Meza-Junco, J et al. (2015) Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia, Sarcopenia Muscle (epublication ahead of print version)
6. Roubenoff, R (2000) Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann N Y Acad Sci 904, 553557.
7. Wannamethee, SG & Atkins, JL (2015) Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 74, 405412.
8. Baracos, VE (2006) Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 26, 435461.
9. Martin, L, Senesse, P, Gioulbasanis, I et al. (2015) Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33, 9099.
10. Prado, CM, Lieffers, JR, McCargar, LJ et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9, 629635.
11. Prado, CM & Heymsfield, SB (2014) Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parent Enteral Nutr 38, 940953.
12. Prado, CM, Birdsell, LA & Baracos, VE (2009) The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3, 269275.
13. Shen, W, Punyanitya, M, Wang, Z et al. (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97, 23332338.
14. Chung, H, Cobzas, D, Lieffers, JR et al. (2009) Muscle and adipose tissue segmentation in CT images. Automated Segmentation of Muscle and Adipose Tissue on CT Images for Human Body Composition Analysis 7261.
15. Mitsiopoulos, N, Baumgartner, RN, Heymsfield, SB et al. (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85, 115122.
16. Miller, KD, Jones, E, Yanovski, JA et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871875.
17. Lieffers, JR, Bathe, OF, Fassbender, K et al. (2012) Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 107, 931936.
18. Baracos, VE, Reiman, T, Mourtzakis, M et al. (2010) Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91, 1133S1137S.
19. Cushen, SJ, Power, DG, Teo, MY et al. (2014) Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol (In the Press).
20. Martin, L, Birdsell, L, Macdonald, N et al. (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31, 15391547.
21. von Haehling, S, Morley, JE & Anker, SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia, Sarcopenia Muscle 1, 129133.
22. Prado, CM, Wells, JC, Smith, SR et al. (2012) Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 31, 583601.
23. Fearon, K, Strasser, F, Anker, SD et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489495.
24. Tan, BH, Birdsell, LA & Martin, L (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15, 69736979.
25. Silva, AM, Shen, W, Heo, M et al. (2010) Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol 22, 7682.
26. Baumgartner, RN, Koehler, KM, Gallagher, D et al. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147, 755763.
27. Mourtzakis, M, Prado, CMM, Lieffers, JR et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33, 9971006.
28. Anandavadivelan, P, Brismar, TB, Nilsson, M et al. (2015) Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr (epublication ahead of print version).
29. Lodewick, TM, van Nijnatten, TJ, van Dam, RM et al. (2015) Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB 17, 438446.
30. Prado, CM, Baracos, VE, McCargar, LJ et al. (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13, 32643268.
31. Prado, CM (2013) Body composition in chemotherapy: the promising role of CT scans. Curr Opin Clin Nutr Metab Care 16, 525533.
32. Prado, CM, Maia, YL, Ormsbee, M et al. (2013) Assessment of nutritional status in cancer – the relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 13, 11971203.
33. Prado, CM, Lima, IS, Baracos, VE et al. (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67, 93101.
34. Prado, CM, Baracos, VE, Xiao, J et al. (2014) The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab 39, 693698.
35. Narjoz, C, Cessot, A, Thomas-Schoemann, A et al. (2015) Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs 33, 257268.
36. Prado, CM, Antoun, S, Sawyer, MB et al. (2011) Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care 14, 250254.
37. Antoun, S, Birdsell, L, Sawyer, MB et al. (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 28, 10541060.
38. Alberta Health Services. A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US)
39. Stene, GB, Helbostad, JL, Amundsen, T et al. (2015) Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54, 340348.
40. Meza-Junco, J, Montano-Loza, AJ, Baracos, VE et al. (2013) Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 47, 861870.
41. Prado, CMM, Mourtzakis, M, Baracos, V et al. (2010) Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int J Body Compos Res 8, 715.
42. Prado, CM, Baracos, VE, McCargar, LJ et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15, 29202926.
43. Lanic, H, Kraut-Tauzia, J, Modzelewski, R et al. (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55, 817823.
44. Miyamoto, Y, Baba, Y, Sakamoto, Y et al. (2015) Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22, 26632668.
45. Miyamoto, Y, Baba, Y, Sakamoto, Y et al. (2015) Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE 10, e0129742.
46. Fukushima, H, Yokoyama, M, Nakanishi, Y et al. (2015) Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS ONE 10, e0115895.
47. Voron, T, Tselikas, L, Pietrasz, D et al. (2014) Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 261, 11731183.
48. Sharma, P, Zargar-Shoshtari, K, Caracciolo, JT et al. (2015) Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 33, 339 e17–e23.
49. Reisinger, KW, Bosmans, JW, Uittenbogaart, M et al. (2015) Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol 22, 44454452.
50. Okumura, S, Kaido, T, Hamaguchi, Y et al. (2015) Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery 157, 10881098.
51. Reisinger, KW, van Vugt, JL, Tegels, JJ et al. (2015) Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg 261, 345352.
52. Peng, PD, van Vledder, MG, Tsai, S et al. (2011) Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB 13, 439446.
53. Ida, S, Watanabe, M, Yoshida, N et al. (2015) Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol 22, 44324437.
54. Joglekar, S, Asghar, A, Mott, SL et al. (2015) Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol 111, 771775.
55. van Vugt, JL, Braam, HJ, van Oudheusden, TR et al. (2015) Skeletal muscle depletion is associated with severe postoperative complications in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 22, 36253631. doi: 10.1245/s10434-015-4429-z.
56. Di Sebastiano, KM & Mourtzakis, M (2012) A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 37, 811821.
57. Tsai, HK, D'Amico, AV, Sadetsky, N et al. (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99, 15161524.
58. Demark-Wahnefried, W, Peterson, BL, Winer, EP et al. (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19, 23812389.
59. Aubrey, J, Esfandiari, N, Baracos, VE et al. (2014) Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 210, 489497.
60. Sabel, MS, Lee, J, Cai, S et al. (2011) Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18, 35793585.
61. Prado, CM, Sawyer, MB, Ghosh, S et al. (2013) Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98, 10121019.
62. Baracos, VE (2014) Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. doi: 10.1016/S1470-2045(14)71185-4
63. Dobs, AS, Boccia, RV, Croot, CC et al. (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14, 335345.
64. Garcia, JM, Boccia, RV, Graham, CD et al. (2014) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16, 108116.
65. Garcia, JM, Boccia, RV, Graham, CD et al. (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16, 108116.
66. Deutz, NE, Safar, A, Schutzler, S et al. (2011) Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr (Edinburgh, Scotland) 30, 759768.
67. Winter, A, MacAdams, J & Chevalier, S (2012) Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 31, 765773.
68. MacDonald, AJ, Johns, N, Stephens, NA et al. (2014) Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res 21, 17341740.
69. Hutton, JL, Martin, L, Field, CJ et al. (2006) Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 84, 11631170.
70. Institute of Medicine (2005) Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids (Macronutrients). Washington: National Academies Press.
71. Martin, C (2000) Calorie, protein, fluid, and micronutrient requirements. In The Clinical Guide to Oncology Nutrition, p. 270. [McCallum, PD and Polisena, CG, editors]. Chicago: American dietetic association.
72. Bozzetti, F (2013) Nutritional support of the oncology patient. Crit Rev Oncol Hematol 87, 172200.
73. Arends, J, Bodoky, G, Bozzetti, F et al. (2006) ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr (Edinburgh, Scotland) 25, 245259.
74. Prado, CM, Lieffers, JR, Bergsten, G et al. (2012) Dietary patterns of patients with advanced lung or colorectal cancer. Can J Diet Pract Res 73, e298e303.
75. Prado, CMM, Lieffers, JR, Bowthorpe, L et al. (2013) Sarcopenia and physical function: in overweight patients with advanced cancer. Can J Diet Pract Res 74, 6974.
76. Gonzalez, MC, Pastore, CA, Orlandi, SP et al. (2014) Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr 99, 9991005.
77. Mir, O, Coriat, R, Blanchet, B et al. (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7, e37563.
78. Huillard, O, Mir, O, Peyromaure, M et al. (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108, 10341041.
79. Massicotte, MH, Borget, I, Broutin, S et al. (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 98, 24012408.
80. Barret, M, Antoun, S, Dalban, C et al. (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66, 583589.
81. Moryoussef, F, Dhooge, M, Volet, J et al. (2015) Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia, Sarcopenia Muscle 6, 343350.
82. Tan, BH, Brammer, K, Randhawa, N et al. (2015) Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 41, 333338.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed